Carthera, a spin-off from Sorbonne University, has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the use of carboplatin in the treatment of malignant glioma. Carthera is using carboplatin in the first registrational trial of its SonoCloud technology in the treatment of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!